Unsafe and potentially safe herbal therapies

American Journal of Health-System Pharmacy

Volumn 56, Issue 2, 1999, Pages 125-138

  Klepser, Teresa Bailey ^a   Klepser, Michael E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Contraindications; Dosage; Drug interactions; Drugs, clinical effectiveness; Education; Mechanism of action; Patient information; Pharmaceutical; Pharmacists; Plants; Toxicity

Indexed keywords

BORAGE; CHAPARRAL EXTRACT; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; LIFE ROOT; PLANT EXTRACT; UNCLASSIFIED DRUG; VALERIAN;

CALAMUS; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLTSFOOT; COMFREY; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOCRINE DISEASE; EPHEDRA; FATIGUE; GARLIC; GASTROINTESTINAL TOXICITY; GERMANDER; GINSENG; GLYCYRRHIZA; HERB; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INSOMNIA; LIVER TOXICITY; MEDICAL EDUCATION; MEDICINAL PLANT; METABOLIC DISORDER; MIGRAINE; NEPHROTOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RHEUMATOID ARTHRITIS; SABAL; SASSAFRAS; TANACETUM PARTHENIUM;

EID: 0033555737     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.2.125     Document Type: Review

References (95)

1. Eisenberg D, Kessler RC, Foster C et al. Unconventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med. 1993; 328:246-52.
2. Johnston BA. One-third of nation's adults use herbal remedies: market estimated at $3.24 billion. Herbalgram. 1997; 40:49.
3. Miller LG, Murray WJ. Herbal instruction in United States pharmacy schools. Am J Pharm Educ. 1997, 61:160-2.
4. U.S. Senate. S. Rep. 103-410 (103rd Cong., 2nd Sess., 1994).
5. Cottrell K. Herbal products begin to attract the attention of brand-name drug companies. Can Med Assoc J. 1996; 155:216-9.
6. Tyler VE. What pharmacists should know about herbal remedies. J Am Pharm Assoc. 1996; NS36(1):29-37.
7. Alderman S, Kailas S, Goldfarb S et al. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. J Clin Gastroenterol. 1994; 19(3):242-7.
8. Larrey D, Vial T, Pauwels A et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992; 117: 129-32.
9. Ben Yahia M, Mavier P, Metreau JM et al. Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases. Gastroenterol Clin Biol. 1993; 17:959-62.
10. Walker BR, Edwards CRW. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metal Clin North Am. 1994; 23:359-77.
11. The review of natural products. St. Louis: Facts and Comparisons; 1997.
12. Foster S. Herbs for your health. Loveland, CO: Interweave; 1996.
13. Tyler VE. Herbs of choice: the therapeutic use of phytomedicinals. New York: Haworth; 1994.
14. Awang DVC. Feverfew fever - a headache for the consumer. Herbalgram. 1993; 29:34-6.
15. Hobbs C. Feverfew. Herbalgram 1989; 20:26-35.
16. Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol. 1987; 39:466-70.
17. Heptinstall S, Williamson L, White A et al. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leukocytes. Lancet. 1985; 1:1071-3.
18. Sumner H, Salan U, Knight DW et al. Inhibition of 5-lipoxygenase and cyclooxygenase in leukocytes by feverfew. Biochem Pharmacol. 1992; 43:2313-20.
19. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med. 1982; 8:653-60.
20. Johnson ES. Efficacy of feverfew as prophylactic treatment of migraine. Br Med. 1985; 291:569-73.
21. Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988; 2:189-92.
22. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997; 11: 508-11.
23. De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized, double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996; 3:225-30.
24. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis. 1989; 48:547-9.
25. Tyler VE, Foster S. Herbs and phytomedicinal products. In: Covington TR, Berardi RR, Young LL, eds. Handbook of non-prescription drugs. 11th ed. Washington, DC: American Pharmaceutical Association; 1996:695-713.
26. Ariga T, Oshiba S, Tamada T. Platelet aggregation inhibitor in garlic. Lancet. 1980; 1:150. Letter.
27. Silagy CA, Neil HAW. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994; 12:463-8.
28. Kandziora J. Antihypertensive effectiveness and tolerance of a garlic medication. Arztl Forsch. 1988; 35(1):1-8.
29. Auer W, Eiber A, Hertkorn E et al. Hypertension and hyperlipidaemia: garlic helps in mild cases. Br J Clin Pract Symp Suppl. 1990; 69:3-6.
30. Vorberg G, Schneider B. Therapy with garlic: results of a placebo-controlled, double-blind study. Br J Clin Pract Symp Suppl. 1990; 69:7-11.
31. Kiesewetter H, Jung F, Pindur G et al. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. Int J Clin Pharmacol. 1991; 29:151-5.
32. Santos OS, Grunwald J. Effect of garlic powder tablets on blood lipids and blood pressure. A six month placebo-controlled double-blind study. Br J Clin Res. 1993; 4:37-44.
33. Jain AK, Vargas R, Gotzkowsky S et al. Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med. 1993; 94:632-5.
34. Kandziora J. The blood pressure lowering and lipid lowering effect of a garlic preparation in combination with a diuretic. Arztl Forsch. 1988; 35(3):1-8.
35. Holzgartner H, Schmidt U, Kuhn U. Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate. Arzneimittelforschung. 1992; 42:1473-7.
36. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med. 1993; 119: 599-605.
37. Mader FH. Treatment of hyperlipidaemia with garlic-powder tablets. Evidence from the German Association of General Practitioners' multicentric placebo-controlled double-blind study. Arzneimittelforschung. 1990; 40:1111-6.
38. Plengvidhya C, Chinayon S, Sitprija S et al. Effects of spray dried garlic preparation on primary hyperlipoproteinemia. J Med Assoc Thai. 1988; 71:248-52.
39. Lau BH, Lam F, Wang-Cheng R. Effect of an odor modified garlic preparation on blood lipids. Nutr Res. 1987; 7:139-49.
40. Reuter HD. Allium sativum and Allium ursinum: part 2. Pharmacology and medicinal application. Phytomedicine. 1995; 2(1):73-91.
41. Tyler VE. The honest herbal. 3rd ed. New York: Haworth; 1993.
42. Pincemail J, Dupuis M, Nasr C et al. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia. 1989; 45:708-12.
43. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet. 1992; 340: 1136-9.
44. Koltai M, Hosford D, Guinot P et al. Platelet activating factor (PAF): a review of its effects, antagonists and possible future clinical implications (part I). Drugs. 1991; 42:9-29.
45. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992; 34:352-8.
46. Schmidt U, Rabinovici K, Lande S. Einfluss eines Ginkgo-biloba-Spezialextraktes auf die Befindlichkeit bei zerebraler Insuffizienz. Münch Med Wochenschr. 1991; 133(suppl 1):S15-8.
47. Brüchert E, Heinrich SE, Ruf-Kohler P. Wirksamkeit von LI 1370 bei älteren Patienten mit Hirnleistungsschwäche. Multizentrische Doppelblindstudie des Fachverbandes Deutischer Allgemeinärzte. Münch Med Wochenschr. 1991; 133(suppl 1): S9-14.
48. Meyer B. Étude multicentrique randomisée à double insu face au placebo du traitment des acouphènes par l'extrait de Ginkgo biloba. Presse Med. 1986; 15:1562-4.
49. Taillander J, Ammar A, Rabourdin JP et al. Traitement des troubles du vieillissement cérébral par l'extrait de Ginkgo biloba. Presse Med. 1986; 15:1583-7.
50. Haguenauer JP, Cantenot F, Koskas H et al. Traitment des troubles de l'équilibre par l'extrait de Ginkgo biloba. Etude multicentrique à double insu face au placebo. Presse Med. 1986; 15:1569-72.
51. Vorberg G, Schenk N, Schmidt U. Wirksamkeit eines neuen Ginkgo-biloba-Extraktes bei 100 Patienten mit zerebraler Insuffizienz. Herz Gefässe. 1989; 9:936-41.
52. Eckmann VF. Hirnleistungsstörungern-Behandlung mit Ginkgo-biloba-Extrakt. Fortschr Med. 1990; 108:557-60.
53. Wesnes K, Simmons D, Rook M et al. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol. 1987; 2:159-69.
54. Bauer U. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung. 1984; 34:716-20.
55. Saudreau F, Serise JM, Pillet J et al. Efficacité de l'extrait de Ginkgo biloba dans le traitement des artériopathies oblitérantes chroniques des membres inférieurs as stade III de la classification de fontaine. J Mal Vasc. 1989; 14:177-82.
56. Le Bars PL, Katz MM, Berman N et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997; 278:1327-32.
57. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med. 1997; 336:1108. Letter.
58. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-6.
59. Gilbert GJ, Ginkgo biloba. Neurology. 1997; 48:1137. Letter.
60. Bisset NG, ed. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. Boca Raton, FL: CRC; 1994.
61. Bahrke MS, Morgan WP. Evaluation of the ergogenic properties of ginseng. Sports Med. 1994; 18:229-48.
62. Chong SKF, Oberholzer VG. Ginseng: is there a use in clinical medicine? Postgrad Med J. 1988; 64:841-6.
63. D'Angelo L, Grimaldi R, Caravaggi M et al. Double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. J Ethnopharmacol. 1986; 16:15-22.
64. Pieralisi G, Ripari P, Vecchiet L. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, and trace elements on physical performance during exercise. Clin Ther. 1991; 13:373-82.
65. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995; 18:1373-5.
66. Yun TK, Choi SY. Preventive effect of ginseng intake and cancer. Int J Epidemiol. 1995; 19:871-86.
67. Hobbs C. Ginseng: facts and folklore, Herbs Health. 1997; 2:35-8.
68. Shader RI, Greenblatt DJ. Phenelzine and the dream machine - ramblings and reflections. J Clin Psychopharmacol. 1985; 5(2):65. Editorial.
69. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol. 1987; 7(3):201-2. Letter.
70. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm. 1997; 54:692-3.
71. Siegel RK. Ginseng abuse syndrome: problems with the panacea. JAMA. 1979; 241:1614-5.
72. Siegel RK. Ginseng and high blood pressure. JAMA. 1980; 243:32. Letter.
73. Greenspan EM. Ginseng and vaginal bleeding. JAMA. 1983; 249:2018. Letter.
74. Punnonen R, Lukola A. Oestrogen-like effect of ginseng. Br Med J. 1980; 281:1110.
75. Leung AY. Better health with (mostly) Chinese herbs and food. Glen Rock, NJ: AYSL; 1995.
76. Carilla E, Briley M, Fauran F et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 1984; 20(1):521-3.
77. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996; 9:379-95.
78. Carraro JC, Raynaud JP, Koch G et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996; 29(4):231-40.
79. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996; 335:533-9.
80. Tenover JL, Pagano GA, Morton AS et al. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther. 1997; 19:243-58.
81. Semino MA, Ortega JLL, Cobo EG et al. Tratamiento sintomático de la hipertrofia benigna de próstata. Estudio comparativo entre prazosin y Serenoa repens. Arch Esp Urol. 1992; 45:211-3.
82. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol. 1984; 18:461-2.
83. Reece Smith H, Memon A, Smart CJ et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol. 1986; 58:36-40.
84. Descotes JL, Rambeaud JJ, Deschaseaux P et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995; 9(5):291-7.
85. American herbal pharmacopoeia. St. John's wort: Hypericum perforatum. Herbalgram. 1997; 40:1-32.
86. Suzuki O, Katsumata Y, Oya M et al. Inhibition of monoamine oxidase by hypericin. Planta Med. 1984; 50:272-4.
87. Hobbs C. St. John's wort - Hypericum perforatum. Herbalgram. 1989; 18/19:24-33.
88. Linde K, Ramirez G, Mulrow CD et al. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 1996; 313:253-8.
89. Mills KC. Serotonin syndrome: a clinical update. Crit Care Clin. 1997; 13:763-83.
90. Woelk H, Burkard G, Grünwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol. 1994; 7(suppl 1):S34-8.
91. Awang DVC. Herbal medicine: St. John's wort. Can Pharm J. 1991; 124:33-5.
92. Houghton PJ. The biological activity of valerian and related plants. J Ethnopharmacol. 1988; 22:121-42.
93. Leathwood PD, Chauffard F, Heck E et al. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982; 17:65-71.
94. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 1985; 51:144-8.
95. Hobbs C. Valerian - a literature review. Herbalgram. 1989; 21:19-34.